Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346548 | 0.88 | RET (0.47) | MAPK8ULK1RETMAPK9MAPK10 | |
| SCHEMBL10165915 | 0.75 | MAPK8 (0.56) | MAPK8ULK1RETMAPK9MAPK10 | |
| SCHEMBL16266502 | 0.74 | MAPK1 (0.53) | LRRK2MAPK8ULK1RETMAPK9 | |
| SCHEMBL30407002 | 0.74 | ULK1 (0.48) | MAPK8ULK1RETPAK1MAPK9 | |
| SCHEMBL27362986 | 0.72 | MAPK1 (0.53) | MAPK8LATS1LATS2PDE10AMAPK9 | |
| SCHEMBL22241892 | 0.70 | JAK1 (0.52) | MAPK8JAK3MAPK9MAPK10 | |
| SCHEMBL11916208 | 0.70 | ULK1 (0.46) | LRRK2ULK1MAPK1 | |
| SCHEMBL30219582 | 0.70 | ULK1 (0.46) | LRRK2ULK1MAPK1 | |
| SCHEMBL25520203 | 0.68 | DYRK1A (0.42) | LATS1LATS2RETPDE10A | |
| SCHEMBL16266511 | 0.67 | ULK1 (0.48) | ULK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | LRRK2 729/4885MAPK8 1482/4885LATS1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.